Nabriva Therapeutics plc NBRVF · Stock Open Nabriva Therapeutics plc in new tab
Nabriva Therapeutics plc Analysis (NBRVF)
Is Nabriva Therapeutics plc a good investment? Nabriva Therapeutics plc (NBRVF) is currently trading at 0.000100 USD.
Earnings Schedule: Nabriva Therapeutics plc is expected to release its next earnings report on Aug. 6, 2026.
Investor FAQ
Does Nabriva Therapeutics plc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Nabriva Therapeutics plc?
Nabriva Therapeutics plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -18.37.
Company Profile
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONTEPO for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorpora.ted in 2005 and is headquartered in Dublin, Ireland.
| Split Date | Split Ratio to 1 |
|---|---|
| June 26, 2017 | 10.000000 |
| Dec. 3, 2020 | 0.100000 |
| Sept. 16, 2022 | 0.040000 |
Community Discussion